

Patent Claims for USA:

92/B 024 - Ma 957

- 184
185
1. A compound containing an antigen binding region which is bound to at least one prodrug-activating enzyme, where the antigen binding region is composed of a single polypeptide chain.
 2. A compound as claimed in claim 1, wherein the compound carries covalently bonded carbohydrates.
 3. A compound as claimed in claim 1, wherein the antigen binding region contains a variable domain of a heavy antibody chain and a variable domain of a light antibody chain (sFv fragment).
 4. A compound as claimed in claim 1, wherein the antigen binding region binds to a tumor-associated antigen (TAA).
 5. A compound as claimed in claim 3, wherein the TAA is an N-CAM, PEM, EGF-R, Sialyl-Le^a, Sialyl-Le^x, TFB, GICA, GD₃, GD₂, TAG72, CA125, the 24-25 kDa glycoprotein defined by MAb L6, or CEA, preferably a CEA.
 6. A compound as claimed in claim 1, wherein the enzyme is a lactamase, preferably a Bacillus cereus II B-lactamase, pyroglutamate aminopeptidase, D-aminopeptidase, oxidase, peroxidase, phosphatase, hydroxynitrile lyase, protease, esterase, carboxypeptidase, preferably a carboxypeptidase G2 from Pseudomonas or glycosidase.

7. A compound as claimed in claim 6, wherein the enzyme is a β -glucuronidase, preferably a *E.coli*, *Kobayasia nipponica*, *Secale cereale* or human β -glucuronidase.
8. A compound as claimed in claim 1, wherein the antigen binding region is linked to the enzyme via a peptide linker.
9. A compound as claimed in claim 1, wherein the glycosylation takes place either by means of chemical methods or by a selection of suitable expression systems.
10. A compound as claimed in claim 1, which undergoes secretory expression in *Saccharomyces cerevisiae* or, more advantageously, in *Hansenula polymorpha*.
11. A compound as claimed in claim 1, which is expressed in *E. coli* and is subsequently chemically glycosylated, preferably galactosylated and/or mannosylated.
12. A compound as claimed in claim 1, wherein the sFv- β -lactamase fusion protein, which has undergone periplasmic expression in *E. coli*, is chemically glycosylated, preferably galactosylated and/or mannosylated.
13. A compound as claimed in claim 1, wherein the sFv- β -lactamase fusion protein undergoes secretory expression in *Saccharomyces cerevisiae* or *Hansenula polymorpha*.
14. A nucleic acid coding for a compound as claimed in claim 1.

15. A nucleic acid as claimed in claim 14, coding for a humanized sFv fragment against CEA and a human β -glucuronidase.

16. A nucleic acid as claimed in claim 14 with the sequence

CCAAGCTTAT GAATATGCAA ATCCTGCTCA TGAATATGCA AATCCTCTGA	50
ATCTACATGG TAAATATAGG TTTGTCTATA CCACAAACAG AAAAACATGA	100
GATCACAGTT CTCTCTACAG TTAAGTACAG CACAGGACCT CACC ATG GGA TGG	153
	Met Gly Trp
AGC TGT ATC ATC CTC TTC TTG GTA GCA ACA GCT ACA GGTAAGGGGC	199
Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr	
-10	
TCACAGTAGC AGGCTTGAGG TCTGGACATA TATATGGGTG ACAATGACAT	249
CCACTTTGCC TTTCTCTCCA CA GGT GTC CAC TCC CAG GTC CAA CTG CAG	298
	Gly Val His Ser Gln Val Gln Leu Gln
1	
GAG AGC GGT CCA GGT CTT GTG AGA CCT AGC CAG ACC CTG AGC CTG	343
Glu Ser Gly Pro Gly Leu Val Arg Pro Ser Gln Thr Leu Ser Leu	
10	
ACC TGC ACC GTG TCT GGC TTC ACC ATC AGC AGT GGT TAT AGC TGG	388
Thr Cys Thr Val Ser Gly Phe Thr Ile Ser Ser Gly Tyr Ser Trp	
30	
CAC TGG GTG AGA CAG CCA CCT GGA CGA GGT CTT GAG TGG ATT GGA	433
His Trp Val Arg Gln Pro Pro Gly Arg Gly Leu Glu Trp Ile Gly	
40	
TAC ATA CAG TAC AGT GGT ATC ACT AAC TAC AAC CCC TCT CTC AAA	478
Tyr Ile Gln Tyr Ser Gly Ile Thr Asn Tyr Asn Pro Ser Leu Lys	
60	
AGT AGA GTG ACA ATG CTG GTA GAC ACC AGC AAG AAC CAG TTC AGC	523
Ser Arg Val Thr Met Leu Val Asp Thr Ser Lys Asn Gln Phe Ser	
70	
CTG AGA CTC AGC AGC GTG ACA GCC GCC GAC ACC GCG GTC TAT TAT	568
Leu Arg Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr	
90	
TGT GCA AGA GAA GAC TAT GAT TAC CAC TGG TAC TTC GAT GTC TGG	613
Cys Ala Arg Glu Asp Tyr Asp Tyr His Trp Tyr Phe Asp Val Trp	
100	
GGC CAA GGG ACC ACG GTC ACC GTC TCC TCA GGA GGC GGT GGA TCG	658
Gly Gln Gly Thr Thr Val Thr Val Ser Ser <u>Gly Gly Gly Gly Ser</u>	
120	
GGC GGT GGT GGG TCG GGT GGC GGC GGA TCT GAC ATC CAG CTG ACC	703
<u>Gly Gly Gly Gly Ser Gly Gly Gly Ser</u> Asp Ile Gln Leu Thr	
130	
CAG AGC CCA AGC AGC CTG AGC GCC AGC GTG GGT GAC AGA GTG ACC	748
Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr	
150	

ATC ACC TGT AGT ACC AGC TCG AGT GTA AGT TAC ATG CAC TGG TAC	793
Ile Thr Cys Ser Thr Ser Ser Ser Val Ser Tyr Met His Trp Tyr	
160	
CAG CAG AAG CCA GGT AAG GCT CCA AAG CTG CTG ATC TAC AGC ACA	838
Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ser Thr	
170	
TCC AAC CTG GCT TCT GGT GTG CCA AGC AGA TTC AGC GGT AGC GGT	883
Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly	
180	
AGC GGT ACC GAC TTC ACC TTC ACC ATC AGC AGC CTC CAG CCA GAG	928
Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu	
190	
GAC ATC GCC ACC TAC TAC TGC CAT CAG TGG AGT AGT TAT CCC ACG	973
Asp Ile Ala Thr Tyr Tyr Cys His Gln Trp Ser Ser Tyr Pro Thr	
200	
TTC GGC CAA GGG ACC AAG CTG GAG ATC AAA GGTGAGTAGA ATTTAAACTT	1023
Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys	
210	
TGCTTCCTCA GTTGGATCTG AGTAACTCCC AATCTTCTCT CTGCA GAG CTC AAA	1077
220	
ACC CCA CTT GGT GAC ACA ACT CAC ACA TGC CCA CGG TGC CCA	1119
Thr Pro Leu Gly Asp Thr Thr His Thr Cys Pro Arg Cys Pro	
230	
GGTAAGCCAG CCCAGGACTC GCCCTCCAGC TCAAGGCGGG ACAAGAGCCC	1169
240	
TAGAGTGGCC TGAGTCCAGG GACAGGCCCC AGCAGGGTGC TGACGCATCC	1219
250	
ACCTCCATCC CAGATCCCCG TAACTCCCAA TCTTCTCTCT GCA GCG GCG GCG	1271
Ala Ala Ala	
260	
GCG GTG CAG GGC GGG ATG CTG TAC CCC CAG GAG AGC CCG TCG CGG	1316
Ala Val Gln Gly Gly Met Leu Tyr Pro Gln Glu Ser Pro Ser Arg	
270	
GAG TGC AAG GAG CTG GAC GGC CTC TGG AGC TTC CGC GCC GAC TTC	1361
Glu Cys Lys Glu Leu Asp Gly Leu Trp Ser Phe Arg Ala Asp Phe	
280	
TCT GAC AAC CGA CGC CGG GGC TTC GAG GAG CAG TGG TAC CGG CGG	1406
Ser Asp Asn Arg Arg Arg Gly Phe Glu Glu Gln Trp Tyr Arg Arg	
290	
CCG CTG TGG GAG TCA GGC CCC ACC GTG GAC ATG CCA GTT CCC TCC	1451
Pro Leu Trp Glu Ser Gly Pro Thr Val Asp Met Pro Val Pro Ser	
300	
AGC TTC AAT GAC ATC AGC CAG GAC TGG CGT CTG CGG CAT TTT GTC	1496
Ser Phe Asn Asp Ile Ser Gln Asp Trp Arg Leu Arg His Phe Val	
310	
GGC TGG GTG TGG TAC GAA CGG GAG GTG ATC CTG CCG GAG CGA TGG	1541
Gly Trp Val Trp Tyr Glu Arg Glu Val Ile Leu Pro Glu Arg Trp	
320	
ACC CAG GAC CTG CGC ACA AGA GTG GTG CTG AGG ATT GGC AGT GCC	1586
Thr Gln Asp Leu Arg Thr Arg Val Val Leu Arg Ile Gly Ser Ala	
330	
CAT TCC TAT GCC ATC GTG TGG GTG AAT GGG GTC GAC ACG CTA GAG	1631
His Ser Tyr Ala Ile Val Trp Val Asn Gly Val Asp Thr Leu Glu	
340	
350	
360	
370	
380	

CAT His	GAG Glu	GGG Gly	GGC Gly	TAC Tyr	CTC Leu	CCC Pro	TTC Phe	GAG Glu	GCC Ala	GAC Asp	ATC Ile	AGC Ser	AAC Asn	CTG Leu	1676
GTC Val	CAG Gln	GTG Val	GGG Gly	CCC Pro	CTG Leu	CCC Pro	TCC Ser	CGG Arg	CTC Leu	CGA Arg	ATC Ile	ACT Thr	ATC Ile	GCC Ala	1721
ATC Ile	AAC Asn	AAC Asn	ACA Thr	CTC Leu	ACC Thr	CCC Pro	ACC Thr	ACC Thr	CTG Leu	CCA Pro	CCA Pro	GGG Gly	ACC Thr	ATC Ile	1766
CAA Gln	TAC Tyr	CTG Leu	ACT Thr	GAC Asp	ACC Thr	TCC Ser	AAG Lys	TAT Tyr	CCC Pro	AAG Lys	GGT Gly	TAC Tyr	TTT Phe	GTC Val	1811
CAG Gln	AAC Asn	ACA Thr	TAT Tyr	TTT Phe	GAC Asp	TTT Phe	TTC Phe	AAC Asn	TAC Tyr	GCT Ala	GGA Gly	CTG Leu	CAG Gln	CGG Arg	1856
TCT Ser	GTA Val	CTT Leu	CTG Leu	TAC Tyr	ACG Thr	ACA Thr	CCC Pro	ACC Thr	ACC Thr	TAC Tyr	ATC Ile	GAT Asp	GAC Asp	ATC Ile	1901
ACC Thr	GTC Val	ACC Thr	ACC Thr	AGC Ser	GTG Val	GAG Glu	CAA Gln	GAC Asp	AGT Ser	GGG Gly	CTG Leu	GTG Val	AAT Asn	TAC Tyr	1946
CAG Gln	ATC Ile	TCT Ser	GTC Val	AAG Lys	GGC Gly	AGT Ser	AAC Asn	CTG Leu	TTC Phe	AAG Lys	TTG Leu	GAA Glu	GTG Val	CGT Arg	1991
CTT Leu	TTG Leu	GAT Asp	GCA Ala	GAA Glu	AAC Asn	AAA Lys	GTC Val	GTG Val	GCG Ala	AAT Asn	GGG Gly	ACT Thr	GGG Gly	ACC Thr	2036
CAG Gln	GGC Gly	CAA Gln	CTT Leu	AAG Lys	GTG Val	CCA Pro	GGT Gly	GTC Val	AGC Ser	CTC Leu	TGG Trp	TGG Trp	CCG Pro	TAC Tyr	2081
CTG Leu	ATG Met	CAC His	GAA Glu	CGC Arg	CCT Pro	GCC Ala	TAT Tyr	CTG Leu	TAT Tyr	TCA Ser	TTG Leu	GAG Glu	GTG Val	CAG Gln	2126
CTG Leu	ACT Thr	GCA Ala	CAG Gln	ACG Thr	TCA Ser	CTG Leu	GGG Gly	CCT Pro	GTG Val	TCT Ser	GAC Asp	TTC Phe	TAC Tyr	ACA Thr	2171
CTC Leu	CCT Pro	GTG Val	GGG Gly	ATC Ile	CGC Arg	ACT Thr	GTG Val	GCT Ala	GTC Val	ACC Thr	AAG Lys	AGC Ser	CAG Gln	TTC Phe	2216
CTC Leu	ATC Ile	AAT Asn	GGG Gly	AAA Lys	CCT Pro	TTC Phe	TAT Tyr	TTC Phe	CAC His	GGT Gly	GTC Val	AAC Asn	AAG Lys	CAT His	2261
GAG Glu	GAT Asp	GCG Ala	GAC Asp	ATC Ile	CGA Arg	GGG Gly	AAG Lys	GGC Gly	TTC Phe	GAC Asp	TGG Trp	CCG Pro	CTG Leu	CTG Leu	2306
GTG Val	AAG Lys	GAC Asp	TTC Phe	AAC Asn	CTG Leu	CTT Leu	CGC Arg	TGG Trp	CTT Leu	GGT Gly	GCC Ala	AAC Asn	GCT Ala	TTC Phe	2351
CGT Arg	ACC Thr	AGC Ser	CAC His	TAC Tyr	CCC Pro	TAT Tyr	GCA Ala	GAG Glu	GAA Glu	GTG Val	ATG Met	CAG Gln	ATG Met	TGT Cys	2396
GAC Asp	CGC Arg	TAT Tyr	GGG Gly	ATT Ile	GTG Val	GTC Val	ATC Ile	GAT Asp	GAG Glu	TGT Cys	CCC Pro	GGC Gly	GTG Val	GGC Gly	2441

[illegible]

17. A vector containing a nucleic acid as claimed in claim 14.

18. A host cell containing a nucleic acid as claimed in claim 14 or a vector as claimed in claim 17.

19. A host cell as claimed in claim 18, which is a BHK, CHO, COS, HeLa, insect, tobacco plant, yeast or E.coli cell.

20. A transgenic mammal with the exception of a human, containing a DNA as claimed in claim 14 or a vector as claimed in claim 17.

21. A process for preparing a compound as claimed in claim 1, which comprises

a) introducing a nucleic acid as claimed in claim 14 or a vector as claimed in claim 17 into a host cell,

b) cultivating the host cell, and

c) isolating the compound.

22. A process for preparing a compound as claimed in claim 1, which comprises

a) cultivating a host cell as claimed in claim 18, and

b) isolating the compound.

Sub
E2

Sub
E3

23. The use of the compound as claimed in claim 1 for the preparation of a pharmaceutical or of a diagnostic aid.
24. The use of the compound as claimed in claim 1 for the preparation of a pharmaceutical for the treatment of cancer.
25. A pharmaceutical containing a compound as claimed in claim 1.
26. A diagnostic aid containing a compound as claimed in claim 1.